The Agency for Science Technology & Research (A*STAR) Bioprocessing Technology Institute has patented 3C-like proteinase (3CLpro; Mpro; nsp5) (coronavirus) inhibitors.

Oita University has synthesized tricyclic heterocyclic compounds reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

A group of researchers have disclosed spike glycoprotein (SARS-CoV-2; COVID-19 virus)/ACE2 interaction inhibitors in a new patent.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbisko, Astrazeneca, Code, Gilead, Gritstone, Hookipa, Insilico, Invivyd, Neurogene, Organogenesis, Quince, Spyre, Syndax, Viiv.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Argenx, Autolus, Neurizon, Novavax, Rapt, Recce, Resq, Zai Lab.

Westlake Pharmaceutical (Hangzhou) Co. Ltd. has prepared and tested new 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.

Phase III Scorpio-PEP study results showed Shionogi & Co. Ltd.’s oral antiviral ensitrelvir fumaric acid (Xocova) reduced risk of symptomatic COVID-19 infection in subjects who were exposed to the virus by infected household members.

Phase III Scorpio-PEP study results showed Shionogi & Co. Ltd.’s oral antiviral ensitrelvir fumaric acid (Xocova) reduced risk of symptomatic COVID-19 infection in subjects who were exposed to the virus by infected household members.